Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell Cancer

Published on Jun 6, 2020in Clinical Oncology3.113
· DOI :10.1016/J.CLON.2020.05.016
Kevin J. Harrington98
Estimated H-index: 98
(ICR: Institute of Cancer Research),
S.A. Bhide14
Estimated H-index: 14
(The Royal Marsden NHS Foundation Trust)
+ 12 AuthorsKH Wong4
Estimated H-index: 4
(The Royal Marsden NHS Foundation Trust)
#1Lei Zhang (HUST: Huazhong University of Science and Technology)H-Index: 1
#1Li Zhang (HUST: Huazhong University of Science and Technology)H-Index: 9
Last. Min Zhou (HUST: Huazhong University of Science and Technology)H-Index: 70
view all 18 authors...
Background Cancer patients are regarded as a highly vulnerable group in the current Coronavirus Disease 2019 (COVID-19) pandemic. To date, the clinical characteristics of COVID-19-infected cancer patients are largely unknown. Patients and methods In this retrospective cohort study, we included cancer patients with laboratory confirmed COVID-19 from three designated hospitals in Wuhan, China. The clinical data were collected from medical records from Jan 13, 2020, to Feb 26, 2020. Univariate and ...
595 CitationsSource
#1Iris AnilH-Index: 1
#2Roland ArnoldH-Index: 30
Last. Csilla VárnaiH-Index: 16
view all 30 authors...
The UK Coronavirus Cancer Monitoring Project (UKCCMP) aims to collect, analyse, and disseminate in real time data from the UK cancer centres about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection rates in patients with cancer, and their outcomes in terms of coronavirus disease 2019 (COVID-19). This approach will enable oncologists to gain crucial insights to inform decision making. © 2020 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.
28 CitationsSource
#1Jing Yu (WHU: Wuhan University)H-Index: 7
#2Wen Ouyang (WHU: Wuhan University)H-Index: 10
Last. Conghua Xie (WHU: Wuhan University)H-Index: 25
view all 4 authors...
In December 2019, an outbreak of 2019 novel coronavirus disease (COVID-19) occurred in Wuhan, Hubei, which has been linked to the severe adult respiratory syndrome coronavirus 2 (SARS-CoV-2). It is characterized by rapid human-to-human transmission from droplet contamination.1,2 A report of 138 hospitalized patients from a single institution (Zhongnan Hospital of Wuhan University) indicated that hospital-acquired transmission accounted for 41.3% of these admitted patients, thus implicating the h...
489 CitationsSource
#1Wenhua Liang (Guangzhou Medical University)H-Index: 35
#2Weijie Guan (Guangzhou Medical University)H-Index: 14
Last. Jianxing He (Guangzhou Medical University)H-Index: 52
view all 12 authors...
1,777 CitationsSource
#1Meng-Yuan Dai (WHU: Wuhan University)H-Index: 3
#2Dianbo Liu (Harvard University)H-Index: 13
Last. Hongbing Cai (WHU: Wuhan University)H-Index: 7
view all 38 authors...
Background: The novel COVID-19 outbreak, caused by the SARS-CoV-2 virus and originally detected in December 2019 in Wuhan, China, has affected more than 140 countries and territories as of March 2020. Given that patients with cancer are generally more vulnerable to infections, systematic analysis of diverse cohorts of patients with cancer affected by COVID-19 are needed. Methods: Clinical information from 105 hospitalized patients with cancer and 233 hospitalized patients without cancer, all inf...
431 CitationsSource
#1Barbara Burtness (Yale University)H-Index: 63
#2K.J. Harrington (The Royal Marsden NHS Foundation Trust)H-Index: 4
Last. Jeffrey YorioH-Index: 3
view all 205 authors...
Summary Background Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response. Methods KEYNOTE-048 was a randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries. Participants were stratified by PD-L1 expression, p16 status, and performance status and randomly allocated (1:1:1) to pembrolizumab alone, pembrolizum...
356 CitationsSource
#1Christopher M. Booth (Queen's University)H-Index: 34
#2Elizabeth A. Eisenhauer (Queen's University)H-Index: 69
The last few years have seen an increase in the number of randomized controlled trials (RCTs) of new agents in metastatic solid tumors using progression-free survival (PFS) as the primary end point. Some trials showing improvement in PFS, without a correspondingincreaseinoverallsurvival(OS),haveledtoapprovalofnew drugs and/or changes in standard of care. This suggests a growing belief in the oncology community that delaying progression in metastaticdiseaseisaworthygoal,evenifOSisnotimproved.Buti...
218 CitationsSource
#1Jan B. Vermorken (University of Antwerp)H-Index: 87
#2Ricard MesiaH-Index: 29
Last. Ricardo Hitt (Complutense University of Madrid)H-Index: 31
view all 18 authors...
Background Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck. Methods We randomly assigned 220 of 442 eligible patients with untreated recurrent or metastatic squamous-cell carcinoma of the head and neck to receive cisplatin (at a dose of 100 mg per ...
2,229 CitationsSource
Cited By2
#1Ifigenia Vasiliadou (Guy's and St Thomas' NHS Foundation Trust)H-Index: 1
Last. S.A. Bhide (The Royal Marsden NHS Foundation Trust)H-Index: 14
view all 0 authors...
Abstract null null Background null The onset of the COVID-19 pandemic necessitated rapid changes to the practice of head and neck oncology. This survey was conducted to assess the pre-Covid-19 pandemic standard of practice for head and neck oncology patients and the treatment modifications introduced during the Covid-19 pandemic in UK. null null null Methodology null The UK National Cancer Research Institute (NCRI) Head and Neck Clinical Studies Group initiated a multi-centre survey using questi...
#1Sara Walker (Beatson West of Scotland Cancer Centre)
#2M. Thomson (Beatson West of Scotland Cancer Centre)H-Index: 4
Last. C. Wilson (Beatson West of Scotland Cancer Centre)H-Index: 5
view all 2 authors...
#1Sara Walker (Beatson West of Scotland Cancer Centre)
#2M. Thomson (Beatson West of Scotland Cancer Centre)H-Index: 4
Last. Claire Paterson (Beatson West of Scotland Cancer Centre)H-Index: 5
view all 11 authors...
Background Patients with cancer are considered at higher risk of COVID-19 infection and increased severity of infection. Anti-cancer treatment may further increase those risks. The aim of this work is to report early outcomes in patients with head and neck cancer (HNC) treated during the pandemic. Materials and Methods A retrospective cohort study in a UK tertiary level oncology centre between 1st March and 23 June 2020, including patients with HNC who were either newly diagnosed, had developed ...